AAV VP2 Fusion Capsids for Cell-Specific Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing AAV vectors face challenges with low transduction efficacy and broad tropism, requiring high doses for effective gene therapy, and there is a need for improved cell-type selectivity and targeting specificity.
Innovation Solution
AAV VP2 fusion polypeptides comprising an AAV VP2 capsid polypeptide fused with a polypeptide ligand, which can bind to specific cell surface molecules, enhancing transduction and tropism, and are incorporated into rAAV virions for targeted gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If AAV vectors with broad tropism are used, then host range and ability to transduce various cell types is improved, but transduction efficacy in specific target organs is low and high vector doses are required
Solution Approach 1:
The patent applies local quality by fusing specific polypeptide ligands to the N-terminus of the AAV VP2 capsid polypeptide. This modification creates localized targeting functionality at specific regions of the capsid protein, enabling the vector to maintain its broad host range while gaining enhanced specificity for particular target organs through the ligand's selective binding properties.
Solution Approach 2:
The invention creates composite capsid structures by combining the AAV VP2 capsid polypeptide with exogenous polypeptide ligands. This composite approach integrates the advantageous properties of both components: the AAV capsid provides broad tropism and viral function, while the fused ligand confers targeted binding to specific cell surface receptors, thereby resolving the contradiction between broad adaptability and specific transduction efficacy.
2Reliability
If high vector doses are applied to achieve effective transduction, then transduction efficacy is improved, but safety profile deteriorates due to off-target effects and immunogenicity
Solution Approach 1:
By introducing polypeptide ligands with specific binding properties to the VP2 capsid, the patent creates localized targeting functionality that directs the viral vector preferentially to intended target organs. This reduces off-target transduction and allows effective gene delivery at lower vector doses, thereby improving the safety profile while maintaining transduction efficacy.
Solution Approach 2:
The polypeptide ligand acts as an intermediary that mediates specific interaction between the AAV vector and target cell surface receptors. This intermediary binding mechanism enhances targeted delivery efficiency, reducing the need for high vector doses and minimizing harmful off-target effects and immunogenic responses.
3Adaptability or versatility
If polypeptide ligands are fused to the N-terminus of VP2, then targeting specificity and cell-type selectivity are improved, but capsid assembly and decoration levels may be affected
Solution Approach 1:
The patent optimizes the parameters of the fused polypeptide ligands, specifically selecting those with molecular weights of up to 10 kDa. This parameter control ensures that the ligands are small enough to allow proper capsid assembly and incorporation without disrupting the structural integrity or decoration levels of the viral particles, while still providing effective targeting specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV VP2 fusion polypeptides provide improved transduction and targeting specificity, allowing for cell-type specific gene delivery with restricted biodistribution and enhanced safety in therapeutic applications.
Implementation Method 1
the polypeptide ligand, which may have the ability to bind to a cell surface molecule expressed on the at least one tissue or cell type
Data Source
AI summary
This disclosure relates to adeno-associated virus (AAV) VP2 fusion polypeptides comprising an AAV VP2 capsid polypeptide and a polypeptide ligand. The disclosure further relates to rAAV virions comprising such AAV VP2 fusion polypeptides and libraries of nucleic acids encoding such AAV VP2 fusion polypeptides, pharmaceutical compositions comprising such rAAV virions, and related methods and uses.